Shanghai Hyundai Hasen (Shangqiu) Pharmaceutical Co., Ltd.

Shanghai Hyundai Hasen (Shangqiu) Pharmaceutical Co., Ltd. is a production enterprise controlled by Shanghai Hyundai Pharmaceutical Co., Ltd., with more than 800 employees, total assets exceeding 654.38+billion yuan, 654.38+020 pharmaceutical preparations and 65.438+06 bulk drugs. It produces 654.38+05 billion small-volume injections and 654.38+08 billion oral tablets annually.

Our company has the world's most advanced three production lines for small-volume injections I, II and III. Oral solid preparations include tablets, capsules and granules, and the raw materials are 16. All dosage forms and workshops of our company have passed the national GMP certification and obtained the GMP certificate issued by the US Food and Drug Administration. The products meet the requirements of China Pharmacopoeia (CP), British Pharmacopoeia (BP), European Pharmacopoeia (EP) and American Pharmacopoeia.

Our products sell well in 26 provinces, municipalities and autonomous regions, and are exported to Southeast Asia, Latin America, Oceania, Africa and Europe. "Quality first, customer first" is the creed of Shanghai Hyundai Hasen Pharmaceutical Co., Ltd., "Pursuing Excellence and striving for first-class" is the service tenet of modern Hasen people, and modern Hasen cares about life. Every employee treats the quality and brand of the enterprise just like caring for life.

Taking quality as life and health as the foundation embodies the unremitting pursuit and desire of modern Hassan people.